Gliknik
Develops therapies for patients with cancer and immune disorders.
Launch date
Employees
Market cap
-
Enterprise valuation
AUD116m (Public information from Jun 2021)
Baltimore Maryland (HQ)
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
| N/A | $2.9m | Series A | |
$2.4m | Early VC | ||
$3.5m | Early VC | ||
| N/A | $2.0m | Early VC | |
$4.9m | Series B | ||
| N/A | $20.0m | Early VC | |
| N/A | $2.8m | Early VC | |
$15.0m | Early VC | ||
$11.5m Valuation: $75.0m | Series C | ||
| Total Funding | AUD100m | ||
Related Content
Recent News about Gliknik
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.